Enorama Pharma AB (publ) (STO:ERMA)

Enorama Pharma AB Ratios and Metrics

Market cap in millions SEK. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 13, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	29	142	203	114	28	171
Market Cap Growth	-79.50%	-29.89%	77.51%	308.04%	-83.60%	-12.51%
Enterprise Value	26	136	194	108	27	171
Last Close Price	0.38	1.91	3.36	2.51	2.95	17.98
PS Ratio	10.46	52.01	12.89	84.29	4.10	13.36
PB Ratio	-1.22	-6.07	26.04	5.86	0.89	8.01
P/TBV Ratio	-	-	26.04	5.86	0.89	8.01
EV/Sales Ratio	9.35	49.62	12.30	79.67	3.88	13.39
Debt / Equity Ratio	-	-	-	0.02	0.06	0.18
Net Debt / Equity Ratio	0.13	0.13	-0.27	-0.29	-0.07	-0.39
Net Debt / EBITDA Ratio	0.05	0.05	0.04	0.14	0.05	0.32
Net Debt / FCF Ratio	0.05	0.05	0.06	0.14	0.07	0.28
Asset Turnover	0.23	0.23	0.63	0.03	0.14	0.28
Inventory Turnover	2.73	2.73	1.55	1.48	3.66	6.03
Quick Ratio	0.17	0.17	0.43	0.80	0.68	1.77
Current Ratio	0.25	0.25	1.87	1.27	0.95	1.92
Return on Equity (ROE)	-	-	-320.44%	-174.74%	-158.97%	-239.87%
Return on Assets (ROA)	-325.11%	-325.11%	-118.33%	-62.91%	-52.64%	-37.20%
Return on Capital Employed (ROCE)	267.90%	267.90%	-610.00%	-173.10%	-115.60%	-69.60%
Earnings Yield	-262.34%	-52.74%	-21.56%	-38.97%	-149.82%	-16.22%
FCF Yield	-	-41.60%	-17.57%	-36.12%	-117.48%	-17.67%
Buyback Yield / Dilution	-30.99%	-30.99%	-91.50%	-253.96%	-26.23%	-11.44%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.